Oculis Holding AG Ordinary shares (OCS) Stock Price
OCSStock
$12.21−25.32%52W
Market Cap$678.00M
P/E—
PEG Ratio—
Div yield—
Beta0.24
OCS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-70.72%
Price vs S&P 500 (4W)1.15%
VGM Score19.30
OCS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.47 | -$0.20 | +58.17%(+$0.27) | |
| Q1 2026 | -$0.51 | -$0.61 | -19.79%(-$0.10) | |
| Q4 2025 | -$0.51 | -$0.52 | -2.15%(-$0.01) | |
| Q3 2025 | -$0.51 | -$0.40 | +22.25%(+$0.11) | |
| Q2 2025 | -$0.55 | -$0.61 | -9.26%(-$0.05) |
OCS Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.33
4.38
4.38
4.40
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OCSOculis Holding AG Ordinary shares | — | — | F | $12.21 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company developing topical treatments and disease-modifying therapies for ophthalmological conditions. Its pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and related neuro-ophthalmological disorders. The company's candidates target prevalent eye conditions including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.